GMAB
Price
$25.93
Change
+$0.32 (+1.25%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
15.59B
44 days until earnings call
Intraday BUY SELL Signals
MNPR
Price
$81.54
Change
+$12.88 (+18.76%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
546.24M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GMAB vs MNPR

GMAB vs MNPR Comparison Chart in %
View a ticker or compare two or three
VS
GMAB vs. MNPR commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and MNPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (GMAB: $25.61 vs. MNPR: $68.74)
Brand notoriety: GMAB and MNPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 82% vs. MNPR: 80%
Market capitalization -- GMAB: $15.59B vs. MNPR: $460.49M
GMAB [@Biotechnology] is valued at $15.59B. MNPR’s [@Biotechnology] market capitalization is $460.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 1 FA rating(s) are green whileMNPR’s FA Score has 1 green FA rating(s).

  • GMAB’s FA Score: 1 green, 4 red.
  • MNPR’s FA Score: 1 green, 4 red.
According to our system of comparison, MNPR is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 5 TA indicator(s) are bullish while MNPR’s TA Score has 5 bullish TA indicator(s).

  • GMAB’s TA Score: 5 bullish, 4 bearish.
  • MNPR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both GMAB and MNPR are a good buy in the short-term.

Price Growth

GMAB (@Biotechnology) experienced а +4.19% price change this week, while MNPR (@Biotechnology) price change was +11.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

GMAB is expected to report earnings on Aug 06, 2026.

MNPR is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($15.6B) has a higher market cap than MNPR($546M). MNPR YTD gains are higher at: 5.268 vs. GMAB (-16.851). GMAB has higher annual earnings (EBITDA): 1.29B vs. MNPR (-18.71M). GMAB has more cash in the bank: 1.52B vs. MNPR (137M). MNPR has less debt than GMAB: MNPR (132K) vs GMAB (5.35B). GMAB has higher revenues than MNPR: GMAB (3.9B) vs MNPR (0).
GMABMNPRGMAB / MNPR
Capitalization15.6B546M2,857%
EBITDA1.29B-18.71M-6,874%
Gain YTD-16.8515.268-320%
P/E Ratio19.48N/A-
Revenue3.9B0-
Total Cash1.52B137M1,110%
Total Debt5.35B132K4,053,788%
FUNDAMENTALS RATINGS
GMAB vs MNPR: Fundamental Ratings
GMAB
MNPR
OUTLOOK RATING
1..100
1524
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
10057
SMR RATING
1..100
5796
PRICE GROWTH RATING
1..100
5940
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNPR's Valuation (29) in the null industry is somewhat better than the same rating for GMAB (79). This means that MNPR’s stock grew somewhat faster than GMAB’s over the last 12 months.

MNPR's Profit vs Risk Rating (57) in the null industry is somewhat better than the same rating for GMAB (100). This means that MNPR’s stock grew somewhat faster than GMAB’s over the last 12 months.

GMAB's SMR Rating (57) in the null industry is somewhat better than the same rating for MNPR (96). This means that GMAB’s stock grew somewhat faster than MNPR’s over the last 12 months.

MNPR's Price Growth Rating (40) in the null industry is in the same range as GMAB (59). This means that MNPR’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's P/E Growth Rating (16) in the null industry is significantly better than the same rating for MNPR (100). This means that GMAB’s stock grew significantly faster than MNPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABMNPR
RSI
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
63%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
70%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signal:
Gain/Loss:
MNPR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNORX70.75N/A
N/A
Fidelity Nordic
SGRNX44.80N/A
N/A
Allspring Growth Inst
MGRDX48.70N/A
N/A
MFS International Growth R6
PJDAX20.65N/A
N/A
PGIM Jennison Rising Dividend A
JAWGX79.98-0.35
-0.44%
Janus Henderson VIT Global Rsrch Instl

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+1.35%
AXON - GMAB
47%
Loosely correlated
-3.16%
BCAX - GMAB
39%
Loosely correlated
+5.73%
KURA - GMAB
38%
Loosely correlated
+4.33%
RCUS - GMAB
37%
Loosely correlated
+12.01%
ARWR - GMAB
37%
Loosely correlated
+0.18%
More

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+1.88%
QNCX - MNPR
36%
Loosely correlated
-1.85%
GMAB - MNPR
35%
Loosely correlated
+1.35%
ROIV - MNPR
33%
Poorly correlated
-0.64%
IMVT - MNPR
32%
Poorly correlated
+7.81%
PTCT - MNPR
31%
Poorly correlated
+2.60%
More